🇺🇸 FDA
Pipeline program

Genomically Directed Monotherapy

BRE12-158

Phase 2 small_molecule completed

Quick answer

Genomically Directed Monotherapy for Malignant Neoplasm of Breast is a Phase 2 program (small_molecule) at Vera Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Vera Therapeutics
Indication
Malignant Neoplasm of Breast
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials